Skip to main content

Advertisement

SpringerLink
Log in

Liver Injury Associated with the Selective Progesterone Modulator Ulipristal

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 03 August 2020

The Original Article was published on 09 July 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Loue S, Sajatovic M. Encyclopedia of women’s health. Berlin: Springer Science & Business Media; 2004. p. 644.

    Book  Google Scholar 

  2. Mitchell P. Shock as troglitazone withdrawn in UK. Lancet. 1997;350:1685.

    Article  Google Scholar 

  3. Willman D. Life of giving ends in research program. Los Angeles Times. 1998. https://www.latimes.com/archives/la-xpm-1998-dec-06-mn-51278-story.html. Accessed 18 Sep 2020.

  4. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol. 2003;98:175–9.

    Article  CAS  PubMed  Google Scholar 

  5. Björnsson B, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Digest Liver Dis. 2006;38:33–8.

    Article  Google Scholar 

  6. Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis. 2007;11:507–24.

    Article  PubMed  Google Scholar 

  7. Kang S, Brinker A, Christopher Jones S, Dimick-Santos L, Avigan MI. An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with ulipristal acetate for the treatment of uterine fibroids. Drug Saf. 2020. https://doi.org/10.1007/s40264-020-00960-1.

    Article  PubMed  Google Scholar 

  8. Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver injury with ulipristal acetate: exploring the underlyingpharmacological basis. Drug Saf. 2020. https://doi.org/10.1007/s40264-020-00975-8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Donnez J. Ulipristal acetat versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:421–32.

    Article  CAS  PubMed  Google Scholar 

  10. Murdoch M, Roberts M. Selective progesterone receptor modulators and their use within gynecology. Obstet Gynaecol. 2014;16:46–50.

    Google Scholar 

  11. Pohl O, Osterloh I, Gotteland JP. Ulipristal acetat-safety and pharmacokinetics following multiple doses of 10-50 mg per day. J Clin Pharm. 2013;38:314–20.

    CAS  Google Scholar 

  12. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111:1229–36.

    Article  Google Scholar 

  13. Fauser BCJM, Donnez J, Bouchard P, et al. Safety after extended repeated doses of ulipristal acetate for uterine fibroids. PLoS One. 2017;12:e0173523.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.

    Article  PubMed  Google Scholar 

  15. European Medicines Agency. EMA starts review of Esmya for uterine fibroids: review triggered by cases of liver injury. 2020. https://www.ema.europa.eu/docs/en_GB/document_library/Referals_document/Esmya_20/Procedure_started/WC500239713.pdf. Accessed 18 Sep 2020.

  16. Donnez J, Arriagada P, Marciniak M, Larrey D. Liver safety parameters of ulipristal acetat for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17:1225–32.

    Article  CAS  PubMed  Google Scholar 

  17. Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110:593–5.

    Article  PubMed  Google Scholar 

  18. European Medicines Agency. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. 2020. https://www.ema.europa.eu/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products. Accessed 18 Sep 2020.

  19. Meunier L, Meszaros M, Pageaux GP, Delay JM, Herrero A, Pinzani V, et al. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol. 2020;44:e45–9.

    Article  CAS  PubMed  Google Scholar 

  20. Lammert C, Einarsson S, Niklasson A, Saha C, Björnsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury (DILI): search for signals. Hepatology. 2008;47:2003–9.

    Article  CAS  PubMed  Google Scholar 

  21. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–9.

    Article  PubMed  Google Scholar 

  22. Lammert C, Niklasson A, Saha C, Björnsson E, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615–20.

    Article  CAS  PubMed  Google Scholar 

  23. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Landspitali University Hospital, Hringbraut, Building H 101, Reykjavík, Iceland

    Einar S. Björnsson

  2. Faculty of Medicine, University of Iceland, Reykjavík, Iceland

    Einar S. Björnsson

Authors
  1. Einar S. Björnsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Einar S. Björnsson.

Ethics declarations

Funding

No sources of funding were received to assist with the writing of this commentary.

Conflicts of interest/competing interests

Einar S. Björnsson has no conflicts of interest that are directly relevant to the content of this commentary.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code Availability

Not applicable.

Author contributions

ESB wrote this manuscript in its entirety. He also read and approved the final version.

Additional information

Invited editorial on: “An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with ulipristal acetat for the treatment of uterine fibroids” by Kang et al and "Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis" by Gatti et al.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Björnsson, E.S. Liver Injury Associated with the Selective Progesterone Modulator Ulipristal. Drug Saf 43, 1201–1204 (2020). https://doi.org/10.1007/s40264-020-01004-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-020-01004-4

Search

Navigation